Fibroblast growth factor 1 attenuates 6-hydroxydopamine-induced neurotoxicity: An in vitro and in vivo investigation in experimental models of parkinson’s disease

American Journal of Translational Research

Volumn 6, Issue 6, 2014, Pages 664-677

  Wei, Xiaojie ^a   He, Songbin ^a   Wang, Zhouguang ^a   Wu, Jiamin ^a   Zhang, Jinjing ^a   Cheng, Yi ^a   Yang, Jie ^a   Xu, Xinlong ^a   Chen, Zaifeng ^a   Ye, Junmin ^b   Chen, Li ^b   Lin, Li ^a   Xiao, Jian ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Department of Anesthesia The First Affliated Hospital Gangnan Medical University   (China)

Author keywords

ER stress; FGF1; Parkinson s disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; FIBROBLAST GROWTH FACTOR 1; NEUROTRANSMITTER; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL BEHAVIORAL TEST; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MTT ASSAY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; YOUNG ADULT;

EID: 84912079075     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. [1] Bandopadhyay R and de Belleroche J. Pathogenesis of Parkinson’s disease: emerging role of molecular chaperones. Trends Mol Med 2010; 16: 27-36.
2. [2] Lee JS, Mendez R, Heng HH, Yang ZQ and Zhang K. Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation. Am J Transl Res 2012; 4: 102-113.
3. [3] Sano R and Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta 2013; 1833: 3460-3470.
4. [4] Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D and Greene LA. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. J Neurosci 2002; 22: 10690-10698.
5. [5] Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C and Lee MK. Accumulation of toxic al-pha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 2012; 32: 3301-3305.
6. [6] Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, Schneider BL and Lee MK. Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J Neurosci 2012; 32: 3306-3320.
7. [7] Sullivan AM and Toulouse A. Neurotrophic factors for the treatment of Parkinson’s disease. Cytokine Growth Factor Rev 2011; 22: 157-165.
8. [8] Chiocco MJ, Harvey BK, Wang Y and Hoffer BJ. Neurotrophic factors for the treatment of Parkinson’s disease. Parkinsonism Relat Disord 2007; 13 Suppl 3: S321-328.
9. [9] Beenken A and Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235-253.
10. [10] Baron O, Ratzka A and Grothe C. Fibroblast growth factor 2 regulates adequate nigrostria-tal pathway formation in mice. J Comp Neurol 2012; 520: 3949-3961.
11. [11] Timmer M, Cesnulevicius K, Winkler C, Kolb J, Lipokatic-Takacs E, Jungnickel J and Grothe C. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. J Neurosci 2007; 27: 459-471.
12. [12] Date I, Notter MF, Felten SY and Felten DL. MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopa-minergic system by stereotaxic injection of acidic fbroblast growth factor (aFGF). Brain research 1990; 526: 156-160.
13. [13] Truong L, Allbutt H, Kassiou M and Henderson JM. Developing a preclinical model of Parkinson’s disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 2006; 169: 1-9.
14. [14] Lee HJ, Shin SY, Choi C, Lee YH and Lee SJ. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2002; 277: 5411-5417.
15. [15] Olson L. Grafts and growth factors in CNS. Basic science with clinical promise. Stereotact Funct Neurosurg 1990; 54-55: 250-267.
16. [16] Garcia de Yebenes J, Yebenes J and Mena MA. Neurotrophic factors in neurodegenerative disorders: model of Parkinson’s disease. Neurotox Res 2000; 2: 115-137.
17. [17] Baird A. Fibroblast growth factors: activities and signifcance of non-neurotrophin neuro-trophic growth factors. Curr Opin Neurobiol 1994; 4: 78-86.
18. [18] Giacobini MM, Stromberg I, Almstrom S, Cao Y and Olson L. Fibroblast growth factors enhance dopamine fber formation from nigral grafts. Brain Res Dev Brain Res 1993; 75: 65-73.
19. [19] Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD and Giusti P. Alpha-synuclein and Parkinson’s disease. FASEB J 2004; 18: 617-626.
20. [20] de Yebenes JG, Pernaute RS, Garrido JM, Rabano A, Albisua J, Rojo A, Mena MA, Ruiz PG, Jorge P, Correa C, Leenders K, Antonini A, Gunther I, Psylla M and Vontobel P. Long-term intracerebral infusion of fbroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. Parkinsonism Relat Disord 1998; 4: 147-158.
21. [21] Lin L, Yang J, Lin R, Yu L, Gao H, Yang S and Li X. In vivo study on the monoamine neurotrans-mitters and their metabolites change in the striatum of Parkinsonian rats by liquid chroma-tography with an acetylene black nanoparti-cles modifed electrode. J Pharm Biomed Anal 2013; 72: 74-79.
22. [22] Mercado G, Valdes P and Hetz C. An ERcentric view of Parkinson’s disease. Trends Mol Med 2013; 19: 165-175.
23. [23] Zhou JX, Zhang HB, Huang Y, He Y, Zheng Y, Anderson JP, Gai WP, Liang ZG, Wang Y, Ren XM, Wang Q, Gong XL, Yang J, Wang X, Halliday G and Wang XM. Tenuigenin attenuates alpha-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. CNS Neurosci Ther 2013; 19: 688-694.
24. [24] Hoozemans JJ and Scheper W. Endoplasmic reticulum: the unfolded protein response is tangled in neurodegeneration. Int J Biochem Cell Biol 2012; 44: 1295-1298.
25. [25] Holtz WA and O’Malley KL. Parkinsonian mi-metics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 2003; 278: 19367-19377.
26. [26] Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, Marciniak SJ, Ron D, Przedborski S, Kholodilov N, Greene LA and Burke RE. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of par-kinsonism. J Neurochem 2005; 95: 974-986.
27. [27] Zhang HY, Wang ZG, Lu XH, Kong XX, Wu FZ, Lin L, Tan X, Ye LB and Xiao J. Endoplasmic Reticulum Stress: Relevance and Therapeutics in Central Nervous System Diseases. Mol Neurobiol 2014; [Epub ahead of print].
28. [28] Wan XS, Lu XH, Xiao YC, Lin Y, Zhu H, Ding T, Yang Y, Huang Y, Zhang Y, Liu YL, Xu ZM, Xiao J and Li XK. ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. Mol Neurobiol 2014; 2014: 807874.
29. [29] Tanaka K, Fukuoka S, Kawahara S, Kimoto N and Ogawa N. Effect of cabergoline on increase of several ER stress-related molecules in 6-OHDA-lesioned mice. Neurol Sci 2013; 34: 259-261.
30. [30] Kosuge Y, Taniguchi Y, Imai T, Ishige K and Ito Y. Neuroprotective effect of mithramycin against endoplasmic reticulum stress-induced neurotoxicity in organotypic hippocampal slice cultures. Neuropharmacology 2011; 61: 252-261.
31. [31] Hung CC, Ichimura T, Stevens JL and Bonventre JV. Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem 2003; 278: 29317-29326.
32. [32] Zhang HY, Zhang X, Wang ZG, Shi HX, Wu FZ, Lin BB, Xu XL, Wang XJ, Fu XB, Li ZY, Shen CJ, Li XK and Xiao J. Exogenous basic fbroblast growth factor inhibits ER stress-induced apop-tosis and improves recovery from spinal cord injury. CNS Neurosci Ther 2013; 19: 20-29.
33. [33] Wang Z, Zhang H, Xu X, Shi H, Yu X, Wang X, Yan Y, Fu X, Hu H, Li X and Xiao J. bFGF inhibits ER stress induced by ischemic oxidative injury via activation of the PI3K/Akt and ERK1/2 pathways. Toxicol Lett 2012; 212: 137-146.
34. [34] Bellucci A, Navarria L, Zaltieri M, Falarti E, Bodei S, Sigala S, Battistin L, Spillantini M, Missale C and Spano P. Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson’s disease. J Neurochem 2011; 116: 588-605.
35. [35] Gorbatyuk MS, Shabashvili A, Chen W, Meyers C, Sullivan LF, Salganik M, Lin JH, Lewin AS, Muzyczka N and Gorbatyuk OS. Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther 2012; 20: 1327-1337.
36. [36] Liao Y and Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010; 2: 19-42.
37. [37] Zhang Q, Zhang J, Jiang C, Qin J, Ke K and Ding F. Involvement of ERK1/2 pathway in neuro-protective effects of pyrroloquinoline quinine against rotenone-induced SH-SY5Y cell injury. Neuroscience 2014; 270: 183-191.
38. [38] Sanchez A, Tripathy D, Yin X, Luo J, Martinez J and Grammas P. Pigment epithelium-derived factor (PEDF) protects cortical neurons in vitro from oxidant injury by activation of extracellular signal-regulated kinase (ERK) 1/2 and induction of Bcl-2. Neurosci Res 2012; 72: 1-8.
39. [39] Wu JC, Huang WC, Chen YC, Tu TH, Tsai YA, Huang SF, Huang HC and Cheng H. Acidic fbro-blast growth factor for repair of human spinal cord injury: a clinical trial. J Neurosurg Spine 2011; 15: 216-227.
40. [40] Wu JC, Huang WC, Tsai YA, Chen YC and Cheng H. Nerve repair using acidic fbroblast growth factor in human cervical spinal cord injury: a preliminary Phase I clinical study. J Neurosurg Spine 2008; 8: 208-214.